Skeletalis, Inc.

Skeletalis, Inc. is a US-based company focused on advancing musculoskeletal health through targeted therapies that protect and rebuild bone, addressing conditions such as osteoporosis. Founded in 2025 and headquartered in Boston, US, Skeletalis, Inc. is dedicated to developing innovative solutions for musculoskeletal health.

In November 2025, the company raised USD 8. 00 mn in a funding round led by Pillar, with participation from KdT Ventures, Age1, and Slocum Management. The funding will support the development of treatments for osteoporosis, particularly for post-menopausal women. Skeletalis Bio specializes in advancing musculoskeletal health through its OASIS platform, which utilizes a targeted small-molecule approach for addressing active bone loss.

The company aims to serve healthcare professionals dealing with osteoporosis and related bone diseases, primarily in North America and Europe, enhancing patient outcomes. Skeletalis Bio generates revenue through strategic partnerships and direct transactions with healthcare institutions and providers, focusing on collaborative efforts to ensure the adoption of its innovative therapies in clinical settings. Following the recent funding of USD 8. 00 mn, Skeletalis, Inc.

plans to advance its development of osteoporosis treatments specifically targeting post-menopausal women. The company aims to expand its market presence in North America and Europe by launching new products designed to meet critical healthcare needs in bone health by the end of 2026.